BioSpace News Archive

OncoNano Medicine, Inc. today announced an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, taking place June 2-6, 2023 at McCormick Place, Chicago, Illinois.

A new antidepressant drug candidate being developed by researchers at Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) is said to have mechanistic activity and therapeutic features that set it apart from almost all of the currently approved antidepressants in the U.S.

The Rare Medical Network (RMN) announced the results of a study designed to measure the educational value of the RMN specialty-specific websites to healthcare professionals.

Endologix LLC has announced the online publication of the final five-year results of the LEOPARD Trial in the Journal of Vascular Surgery.

MiNK Therapeutics, Inc. today announced that the Company will release its first quarter 2023 financial results before the market opens on Thursday, May 11, 2023.

Prelude Therapeutics Incorporated today announced that company executives will participate in three upcoming healthcare investment conferences.

Angel Medical Systems Inc., a company focused on improving long-term management of high-risk coronary disease in patients who have survived one or more heart attacks, announced it has changed its corporate name to Avertix Medical Inc., and appointed Tim Moran as President and Chief Executive Officer and Philip Tom as Executive Vice President and Chief Financial Officer, effective immediately.

Ocean Biomedical (NASDAQ: OCEA) announced today that its Scientific Co-founder, Jack A. Elias, MD, published new findings in the peer-reviewed journal Cancer Research that detail the mechanisms behind the role of chitinase 3-like-1 (Chi3L1) in the growth of glioblastoma tumors, providing further evidence of the potential impact of Ocean’s anti-Chi3L1 antibody in suppressing severe glioblastoma tumor growth.

Therini Bio, Inc., a biotech company aimed at developing fibrin-targeted therapies to treat inflammatory neurodegenerative and retinal diseases, today announced the close of a $36M Series A financing round.

Generate:Biomedicines and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to jointly discover and co-develop protein therapeutics for up to five oncology targets in advanced cancers, including small-cell and non-small-cell lung cancer.